PubMed Health⌕ Search

Biomedical subjects

K Rämsch

Publications and source records attributed to K Rämsch.

5 recordsLinked to original sources

Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.

Studies on absorption, plasma concentrations and excretion with (+/-)isopropyl-2-methoxyethyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl) -3,5-pyridinedicarboxylate (nimodipine, Bay e 9736, Nimotop) have been conducted in rat, dog and monkey using the carbon-14-labelled substance and a wide range of doses (0.05-10 mg/kg) administered via different routes (intravenous, oral, intraduodenal). Nimodipine was well absorbed in all species. Peak plasma concentrations of radioactivity were determined 28-40 min (male rat), 60 min (female rat), about 3 h (dog) and 7 h (monkey) after administration. Dependent on the observation period (24-216 h) terminal half-lives for the elimination of radioactivity from plasma ranging between 4.6 h (female rat) and 157 h (dog) were observed. Comparing the AUC, the concentration of unchanged [14C]nimodipine in plasma represented only a small (maximally 37% in dogs after i.v. dose) to negligible (about 1%, monkey after oral dosing) part of the total radioactivity. Excretion of radioactivity via feces and urine was rapid in all species after both oral and intravenous dosing. Fecal (biliary) excretion was the major excretory route in rat and dog. The monkeys excreted about 40 to 50% via the urine. Residues in the body never exceeded 1.5% of the dose. [14C]nimodipine and/or its radiolabelled metabolites were secreted in milk of orally dosed lactating rats. Binding of [14C]nimodipine to plasma proteins of rat and dog was about 97%.

Animals↗

The influence of two histamine H2-receptor antagonists, cimetidine and ranitidine, on the plasma levels and clinical effect of nifedipine and metoprolol.

In six healthy volunteers pharmacokinetic and pharmacodynamic interaction of metoprolol and nifedipine with cimetidine and ranitidine was investigated after 1 week of monotherapy with nifedipine and metoprolol and after 1 week each of combined treatment of these drugs with the H2-receptor antagonists. Ranitidine led to a 50% increase in mean peak plasma levels and in the area under the plasma level time curve (AUC) of metoprolol (p less than 0.05) and to an insignificant 30% rise in these parameters of nifedipine (p less than 0.05). Cimetidine increased metoprolol's peak plasma levels of AUC by about 60% (p less than 0.05) and those of nifedipine by 80% (p less than 0.05). Compared to monotherapy with metoprolol beta blocking activity measured by exercise induced tachycardia was not significantly stronger inhibited under the combined treatment of metoprolol with each of the two H2-receptor antagonists. On the other hand the antihypertensive effect of nifedipine was significantly increased during concurrent administration of cimetidine in seven hypertensive patients when compared with monotherapy.

Adult↗

Drug interactions with nitrendipine.

Interactions between calcium channel blockers like nifedipine and concurrently administered drugs like digoxin or cimetidine have been described in the literature. Therefore, possible interactions of the new calcium channel blocker nitrendipine (20 mg daily) with digoxin (0.5 mg daily), digitoxin (0.1 mg daily), cimetidine (1,000 mg daily), ranitidine (300 mg daily), atenolol (100 mg daily), metoprolol (200 mg daily), and acebutolol (400 mg daily) were studied following 1 week of combined treatment of nitrendipine with each of these drugs. Six healthy volunteers were investigated (mean age, 30.2 +/- 2.1 years; mean body weight, 69.7 +/- 4.7 kg; means +/- SEM). Under nitrendipine monotherapy, maximum plasma levels (Cmax) averaged 41.6 +/- 12.8 ng/ml, and they were reached after 2 h. Mean area under the curve was 131.5 +/- 40 ng ml-1 h, and "oral" plasma clearance (Clpl) amounted to 80.8 +/- 27.5 L/h. The H2 receptor antagonists cimetidine and ranitidine and the digitalis glycosides like digoxin or digitoxin did not alter nitrendipine kinetics significantly. Also simultaneous treatment with beta-blockers did not significantly influence kinetic values of the calcium channel blocker, but atenolol showed a tendency to increase Cmax of nitrendipine to 54.2 +/- 19.7 ng/ml, when its Clpl was distinctly lowered to 42.7 +/- 10.4 L/h (p greater than 0.05 compared with 80.8 +/- 27.5 L/h under nitrendipine monotherapy). Increased digoxin plasma levels and digoxin-induced side-effects were seen under nitrendipine co-administration.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗

[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine].

Simultaneous administration of cimetidine and nifedipine to six healthy volunteers produced an about 80% rise in maximal plasma levels and the area under the plasma level-time curve of nifedipine compared with results on nifedipine administration alone (P less than 0.05). After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml. Ranitidine produced an approximately 25%, nonsignificant, rise in plasma level-time curve and peak plasma levels of nifedipine. Seven hypertensives (WHO stage I and II) had a mean arterial blood pressure level of 127 +/- 2.5 mm Hg after two-week placebo administration, and of 109 +/- 2.38 mm Hg after four weeks of nifedipine alone at 4 X 10 mg daily (P less than 0.01). After additional administration of 1 g cimetidine daily for two weeks the mean blood pressure fell significantly to 95 +/- 3.1 mm Hg (P = 0.02), while blood pressure fell to 103 +/- 3.88 mm Hg after two weeks of additional administration of 300 mg ranitidine daily, a fall which was not significant (P greater than 0.05). The interaction of nifedipine and cimetidine is thus of clinical significance because of its pharmacodynamic effect.

Adult↗